Advances in discovery of novel investigational agents for functional cure of chronic hepatitis B: A comprehensive review of phases II and III therapeutic agents

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

1836

Tables (1-2)

189

Sum=2096

Publishing Process of This Article

Item

Count

Browse

Download

Sum=105

Mar 27, 2024 (publication date) through Dec 25, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Hepatol. Mar 27, 2024; 16(3): 331-343
Published online Mar 27, 2024. doi: 10.4254/wjh.v16.i3.331

Table 1 Novel therapeutic agents for treatment of chronic hepatitis B infection in phase II or III development

Drug name (therapeutic class)	Drug sponsor	Phase
Core/capsid inhibitors
JNJ56136379 (JNJ-6379)	Janssen Pharmaceutics	II
ABI-H0731 (Vebicorvir)	Assembly Biosciences	II
Entry inhibitors
Bulevirtide (Hepcludex, formerly Myrcludex)	Gilead Sciences	III
Small interfering RNA
GSK3228836 (Bepirovirsen)	Ionis Pharmaceuticals	III
VIR-2218	Vir Biotechnology	II
VIR-3314	Vir Biotechnology	II
JNJ-73753989 (JNJ-3989, formerly ARO-HBV)	GlaxoSmithKline Pharmaceuticals	II
Arbutus-729 (AB-729 or Imdusiran)	Arbutus Biopharma	II
HBsAg inhibition
REP 2139/REP 2165	Replicor	II
Toll-like receptor agonists
GS-9620 (Vesatolimod)	Gilead Sciences	II
GS-9688 (Selgantolimod)	Gilead Sciences	II
Therapeutic vaccines
GS-4774	Gilead Sciences	II
BRII-179	Brii Biosciences	II

Citation: Lam R, Lim JK. Advances in discovery of novel investigational agents for functional cure of chronic hepatitis B: A comprehensive review of phases II and III therapeutic agents. World J Hepatol 2024; 16(3): 331-343
URL: https://www.wjgnet.com/1948-5182/full/v16/i3/331.htm
DOI: https://dx.doi.org/10.4254/wjh.v16.i3.331